Kathleen P. Rubinstein

Healthcare Policy Analyst

Houston
T 713.276.1650  |  F 713.751.1717

Kathleen P. Rubinstein is a policy analyst who partners with the Healthcare Industry and Public Policy Teams on developing and implementing strategies for achieving client policy goals and resolving their regulatory concerns. Her professional focus centers on matters involving healthcare policy including regulation under the Medicare and Medicaid programs and implementation of the Affordable Care Act.

Kathleen writes extensively on healthcare industry issues and frequently collaborates with the Healthcare Industry and Public Policy Teams on articles and presentations of topical interest. She is the Editor of the BakerHostetler Health Law Update newsletter and blog. A long time instructor at the University of Houston, Kathleen teaches a graduate seminar on healthcare policy for students of public administration, political science and the law.

Select Experience

  • Works collaboratively on developing policy recommendations and legislative proposals; formulating strategic and tactical work plans and crafting communications strategies.
  • Plans and directs the work of stakeholder advisory groups in formulating solutions to complex policy problems.
More »

Experience

  • Works collaboratively on developing policy recommendations and legislative proposals; formulating strategic and tactical work plans and crafting communications strategies.
  • Plans and directs the work of stakeholder advisory groups in formulating solutions to complex policy problems.
  • Engages in research and analysis of existing and emerging policy topics; serves as an information resource on healthcare industry issues, developments and trends. 
  • Monitors, analyzes and assesses the impact of federal and state actions, legislation and rulemaking and emerging initiatives and proposals.
  • Participates in governmental policy and regulatory interactions at state and federal levels; prepares and manages government filings and submissions.

Recognitions

  • Recognition Award, University of Houston Masters of Public Administration Program 
  • List of Outstanding Graduates, National Association of Schools Public Affairs and Administration

Memberships

  • American Hospital Association
  • American Health Lawyers Association
  • University of Houston MPA Program Alumni Network

Services

Industries

Emerging Issues

Admissions

  • [Not an Attorney]

Education

  • M.A., Public Administration, concentration in Health Policy Studies, University of Houston, 1996
  • B.A., Our Lady of the Lake University, 1992, with honors

Blog

In The Blogs

Previous Next
Health Law Update
OIG Provides Additional Compliance Guidance for Healthcare Governing Boards
April 24, 2015
On April 20, 2015, the HHS Office of Inspector General (HHS OIG), in collaboration with the American Health Lawyers Association (AHLA), the Association of Healthcare Internal Auditors (AHIA), and the Health Care Compliance Association...
Read More ->
Health Law Update
Latest Spike in Prescription Drug Spending Prompts OIG Investigation
April 22, 2015
A new report released by the IMS Institute for Healthcare Informatics shows that U.S. spending on pharmaceuticals increased in 2014 by 13.1 percent, reaching $373.9 billion. This is the highest increase since 2001 when drug spending growth...
Read More ->
Health Law Update
Following FDA’s First Biosimilar License, CMS Issues Guidance on Reimbursement for Biosimilars
April 22, 2015
On March 6, 2015, FDA released a statement announcing its issuance of the first biosimilar license to Zarxio. In the same month, CMS issued a number of guidance documents addressing reimbursement for biosimilars under the Medicare Part B...
Read More ->
Health Law Update
CMS Fines Insurer for Misleading Medicare Part D Beneficiaries
April 20, 2015
The federal agency that oversees Medicare’s prescription drug program has alleged that a major U.S. insurance company misled beneficiaries about the pharmacies included in the company’s drug plan, and imposed a $1 million fine. According...
Read More ->
Health Law Update
OMB Reviewing HRSA Proposed Rule For Civil Monetary Penalties And Ceiling Price Regulations For 340B Drug Discount Program
April 20, 2015
The agency that oversees the 340B Drug Discount Program (340B program) is seeking review by the White House Office of Management and Budget (OMB) of a proposed rule that would use civil monetary penalties to enforce ceiling price...
Read More ->